AIM ImmunoTech (AIM) Total Non-Current Liabilities (2010 - 2025)
AIM ImmunoTech's (AIM) quarterly Total Non-Current Liabilities came in at $7.3 million in Q4 2025, up 71.49% on a QoQ basis from $4.3 million in Q3 2025.
AIM ImmunoTech (AIM) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends
AIM ImmunoTech (AIM) has 13 years of Total Non-Current Liabilities data on file, last reported at $7.3 million in Q4 2025.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (changed N/A YoY) and the FY2025 annual result came in at $7.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $7.3 million in Q4 2025, from $4.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $73.9 million in Q1 2021 to a low of $4.3 million in Q3 2025.
- A 3-year average of $47.2 million and a median of $55.9 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 75.18% — and 2022, when it dropped 26.7%.
- Tracing AIM's Total Non-Current Liabilities over 3 years: stood at $57.7 million in 2021, then slipped by 11.76% to $50.9 million in 2022, then tumbled by 85.61% to $7.3 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $7.3 million (Q4 2025), $4.3 million (Q3 2025), and $50.9 million (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 9.32 Bn |
| 10 | AIM ImmunoTech | 4.46 Mn | -5.50 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.32 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2022 | 50.88 Mn |
| Mar 31, 2022 | 54.15 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 62.92 Mn |
| Jun 30, 2021 | 66.51 Mn |
| Mar 31, 2021 | 73.87 Mn |
| Dec 31, 2020 | 64.40 Mn |
| Sep 30, 2020 | 63.99 Mn |
| Jun 30, 2020 | 49.92 Mn |
| Mar 31, 2020 | 42.17 Mn |
| Dec 31, 2019 | 20.70 Mn |
| Sep 30, 2019 | 22.41 Mn |
| Jun 30, 2019 | 12.93 Mn |
| Mar 31, 2019 | 12.07 Mn |
| Dec 31, 2018 | 12.78 Mn |
| Sep 30, 2018 | 13.77 Mn |
| Jun 30, 2018 | 13.59 Mn |
| Mar 31, 2018 | 15.29 Mn |